

## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
 Estimated average burden  
 hours per response: 0.5

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934  
 or Section 30(h) of the Investment Company Act of 1940

☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

☐ Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

|   |  |  |  |  |   |  |
|---|--|--|--|--|---|--|
| 1. Name and Address of Reporting Person * |  |  | 2. Issuer Name and Ticker or Trading Symbol              |  | 5. Relationship of Reporting Person(s) to Issuer<br>(Check all applicable)                            |  |
| Geist William                             |  |  | BIO-TECHNE Corp [ TECH ]                                 |  | Director 10% Owner<br>Officer (give title below) Other (specify below)<br>PRESIDENT, PROTEIN SCIENCES |  |
| (Last) (First) (Middle)                   |  |  | 3. Date of Earliest Transaction (Month/Day/Year)         |  | 6. Individual or Joint/Group Filing (Check Applicable Line)   |  |
| 614 MCKINLEY PLACE NE                     |  |  | 08/15/2025   |  |   |  |
| (Street)                                  |  |  | 4. If Amendment, Date of Original Filed (Month/Day/Year) |  | X Form filed by One Reporting Person<br>Form filed by More than One Reporting Person                  |  |
| MINNEAPOLIS MN 55413                      |  |  |  |  |   |  |
| (City) (State) (Zip)                      |  |  |  |  |   |  |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) |   | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) |            |        | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|------------|--------|---|--|---|
|                                 |                                      |  | Code                           | V | Amount  | (A) or (D) | Price  |   |  |   |
| Common Stock                    | 08/15/2025                           |  | M                              |   | 2,623   | A          | \$0    | 15,915  | D  |   |
| Common Stock                    | 08/15/2025                           |  | F                              |   | 803   | D          | \$53.6 | 15,112  | D  |   |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) |   | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |     | 6. Date Exercisable and Expiration Date (Month/Day/Year) |                 | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) |                            | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
|--|--|--------------------------------------|--|--------------------------------|---|--|-----|--|-----------------|---|----------------------------|--|--|---|--|
|  |  |                                      |  | Code                           | V | (A)  | (D) | Date Exercisable   | Expiration Date | Title   | Amount or Number of Shares |  |  |   |  |
| Stock Options (Right to Buy)               | \$100.39   |                                      |  |                                |   |  |     | (2)  | 02/01/2029      | Common Stock  | 15,912                     |  | 15,912   | D   |  |
| Stock Options (Right to Buy)               | \$94.52  |                                      |  |                                |   |  |     | (3)  | 08/15/2029      | Common Stock  | 29,600                     |  | 29,600   | D   |  |
| Performance Restricted Stock Units         | (1)  |                                      |  |                                |   |  |     | (4)  | (4)             | Common Stock  | 9,074                      |  | 9,074  | D   |  |
| Performance Stock Options (Right to Buy)   | \$84.61  |                                      |  |                                |   |  |     | (4)  | (4)             | Common Stock  | 24,424                     |  | 24,424   | D   |  |
| Stock Options (Right to Buy)               | \$84.61  |                                      |  |                                |   |  |     | (5)  | 08/15/2030      | Common Stock  | 30,059                     |  | 30,059   | D   |  |
| Restricted Stock Units                     | (1)  |                                      |  |                                |   |  |     | (6)  | (6)             | Common Stock  | 9,911                      |  | 9,911  | D   |  |
| Performance Restricted Stock Units         | (1)  |                                      |  |                                |   |  |     | (7)  | (7)             | Common Stock  | 15,738                     |  | 15,738   | D   |  |
| Restricted Stock Units                     | (1)  | 08/15/2025                           |  | M                              |   | 2,623  |     | (8)  | (8)             | Common Stock  | 2,623                      | \$0  | 5,246  | D   |  |
| Stock Options (Right to Buy)               | \$74.91  |                                      |  |                                |   |  |     | (9)  | 08/15/2034      | Common Stock  | 21,204                     |  | 21,204   | D   |  |
| Performance Restricted Stock Units         | (1)  | 08/15/2025                           |  | A                              |   | 19,355   |     | (10)   | (10)            | Common Stock  | 19,355                     | \$0  | 19,355   | D   |  |
| Restricted Stock Units                     | (1)  | 08/15/2025                           |  | A                              |   | 9,678  |     | (11)   | (11)            | Common Stock  | 9,678                      | \$0  | 9,678  | D   |  |
| Stock Options (Right to Buy)               | \$53.6   | 08/15/2025                           |  | A                              |   | 24,758   |     | (12)   | 08/15/2035      | Common Stock  | 24,758                     | \$0  | 24,758   | D   |  |

## Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.

2. Options to purchase 3,980 shares vest on each of 2/1/2023 and 2/1/2025, and options to purchase 3,976 shares vest on each of 2/1/2024 and 2/1/2026.
3. Options to purchase 7,400 shares vest on each of 8/15/2023, 8/15/2024, 8/15/2025 and 8/15/2026.
4. Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
5. Options to purchase 7,515 shares vest on each of 8/15/2024, 8/15/2025, 8/15/2027, and 7,514 shares vest on 8/15/2026.
6. 9,911 restricted stock units vest on 11/1/2025.
7. Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
8. 2,623 restricted stock units vest on each of 8/15/2025, 8/15/2026 and 8/15/2027.
9. Options to purchase 5,301 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028.
10. Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
11. 3,226 restricted stock units vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.
12. Options to purchase 8,253 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 8,252 shares vest on 8/15/2028.

[/s/ Andrew Nick as Attorney-in-Fact for William Geist pursuant to 08/19/2025 Power of Attorney previously filed](#)

\*\* Signature of Reporting Person                      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**